Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698642 | 0.83 | MEN1 (0.35) | ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL14769307 | 0.81 | MAPT (0.38) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL85289 | 0.81 | MAPT (0.38) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL85472 | 0.80 | MAPT (0.37) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL85286 | 0.79 | MAPT (0.36) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL85517 | 0.75 | ALDH1A1 (0.43) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL19784331 | 0.69 | MAPT (0.44) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL2341343 | 0.69 | MAPT (0.51) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL2341968 | 0.69 | MAPT (0.51) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL2345801 | 0.69 | MAPT (0.51) | MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | MAPT 4773/4885ALDH1A1 207/4885SMN1; SMN2 4702/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | MAPT 4795/4885ALDH1A1 525/4885SMN1; SMN2 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.